BIOQUAL Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of an mRNA Vaccine Against COVID-19 (mRNA-1273)

ROCKVILLE, MD, USA I August 10, 2020 I BIOQUAL announces the publication of the successful testing of an mRNA vaccine in non-human primates. The candidate vaccine, mRNA-1273, was co-developed by scientists at the NIAID Vaccine Research Center and a pharmaceutical company. The animal studies were performed at BIOQUAL. The results were published online in the New England Journal of Medicine. This project has been funded in whole or in part with Federal funds from the NIAID, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00069

Article

KS Corbett et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. New England Journal of Medicine DOI: 10.1056/NEJMoa2024671 (2020).

About BIOQUAL

BIOQUAL has been engaged in development of in-vivo testing programs and has been extensively involved in research efforts to develop vaccines and therapies against emerging diseases including AIDS, Hepatitis, Zika, Chikungunya and many others. The company is now focused on COVID-19 research and is positioned to play an important role in the development of successful vaccines and therapies against this epidemic.

SOURCE: Bioqual

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top